drugset / Trial / NCT05555823
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib
RandomizedParallel-groupDouble-blindOther
Summary
The purpose of this study is to evaluate the safety and tolerability of ascending doses of the MEK-inhibitor zapnometinib (ATR-002) given as single doses (SAD Part) and as multiple doses for 7 days (MAD Part) in healthy subjects.
Timeline
- Start
- 2022-06-23
- Primary completion
- 2023-07-20
- Completion
- 2023-07-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Celecoxib | Other / unclassified | 100 mg | Oral |
| Comparator | Repaglinide | Small molecule | 0.5 mg | Oral |
| Subject | ZAPNOMETINIB | Small molecule | 600 mg | — |
| Subject | ZAPNOMETINIB | Small molecule | 900 mg | — |
Indications
No indication recorded.